Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

Lancet Oncology

Volumn 8, Issue 3, 2007, Pages 219-225

  Martín, Miguel ^a   Ruiz, Amparo ^b   Muñoz, Monserrat ^c   Balil, Ana ^d   García Mata, Jesús ^e   Calvo, Lourdes ^f   Carrasco, Eva ^g   Mahillo, Esther ^h   Casado, Antonio ^a   García Saenz, José Ángel ^a   Escudero, M José ^h   Guillem, Vicente ^b   Jara, Carlos ⁱ   Ribelles, Nuria ^j   Salas, Fernando ^k   Soto, Celia ^l   Morales Vasquez, Flavia ^m   Rodríguez, César A ⁿ   Adrover, Encarna ^o   Mel, José Ramón ^p  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Laboratory of Molecular Biology   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^e Orense Complejo Hospital ^*  (Spain)

^f HOSPITAL JUAN CANALEJO   (Spain)

^g ELI LILLY AND COMPANY   (Spain)

^h GEICAM (Spanish Breast Cancer Research Group)   (Spain)

ⁱ HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^k HOSPITAL NACIONAL GUILLERMO ALMENARA IRIGOYEN   (Peru)

^l Regional Hospital de Especialidades number 30   (Mexico)

^m INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

ⁿ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^o HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^p HOSPITAL XERAL CALDE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CARBOPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HORMONE; HORMONE RECEPTOR; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; BLOOD TOXICITY; BONE PAIN; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CATHETER INFECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LIVER FAILURE; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MONOTHERAPY; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PARTIAL THROMBOPLASTIN TIME; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SENSORY NEUROPATHY; SEPTIC SHOCK; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VISCERAL METASTASIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; TAXOIDS; VINBLASTINE;

EID: 33847138943     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70041-4     Document Type: Article

References (28)

1. Hortobagyi G. Treatment of Breast Cancer. N Engl J Med 339 (1998) 974-984
2. Valero V., Hohnes F., Walters R., et al. Phase II trial of docetaxel: a new, highly effective anti-neoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13 (1995) 2886-2894
3. Ravdin P., Burris H., Cook G., et al. Phase II trial of docetaxel in patients with anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13 (1995) 2879-2885
4. Chan S., Friedrichs K., Noel D., et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17 (1999) 2341-2354
5. Wiserman L., and Spencer C. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs Aging 12 (1998) 305-334
6. Henderson I., Berry D., Demetri G., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21 (2003) 976-983
7. Mamounas E., Bryant J., Lembersky B., et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP-B 28. J Clin Oncol 23 (2005) 3686-3696
8. Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352 (2005) 2302-2313
9. Ershler W. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 11 (2006) 325-335
10. Aapro M., Harper P., Johnson S., and Vermorken J. Developments in cytotoxic chemotherapy: advances in treatment utilising vinorelbine. Crit Rev Oncol Hematol 40 (2001) 251-263
11. Heinemann V. Gemcitabine in metastatic breast cancer. Expert Rev Anticancer Ther 5 (2005) 429-443
12. Sanal S., Gokmen E., Karabulut B., and Sezgin C. Gemcitabine and vinorelbine combination in patients with metastatic breast cancer. Breast J 8 (2002) 171-176
13. Nicolaides C., Dimopoulos M., Samantas E., et al. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: phase II study conducted by the Helenic cooperative Oncology Group. Ann Oncol 11 (2000) 873-875
14. Morabito A., Filippelli G., Palmeri S., et al. The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study. Breast Cancer Res Treat 78 (2003) 29-36
15. Donadio M., Ardine M., Berruti A., et al. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol 52 (2003) 147-152
16. Moser R., Hausmaninger H., Mlineritsch B., et al. Gemcitabine and vinorelbine as first or second line therapy in patients with advanced breast cancer: a prospective phase II trial. Proc Am Soc Clin Oncol 20 (2001) 1973a (abstr)
17. Valenza R., Leonardi V., Gebbia V., et al. Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study. Ann Oncol 11 (2001) 495-496
18. Haider k., Kornek G., Kwasny W., et al. Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor. Breast Cancer Res Treat 55 (1999) 203-211
19. Stathopoulos G., Rigatos S., Perganteas N., et al. Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J Clin Oncol 20 (2001) 37-41
20. Lobo F., Virizuela J., Dorta F., et al. Gemcitabine/vinorelbine in metastatic breast cancer patients previously treated with anthracyclines: results of a phase II trial. Clin Breast Cancer 4 (2003) 46-50
21. Therasse P., Arbuck S., Eisenhauer E., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
22. Livingston R., Ellis G., Gralow J., et al. Dose- intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 15 (1997) 1395-1400
23. Zelek L., Barthier S., Riofrio M., et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92 (2001) 2267-2272
24. Blum J., Jones S., Buzdar A., et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17 (1999) 485-493
25. Blum J., Dieras V., Lo Russo P., et al. Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92 (2001) 1759-1768
26. Modi S., and Seidman A. Single-agent gemcitabine in the treatment of advanced breast cancer. Clin Breast Cancer 4 suppl 3 (2004) S101-S106
27. Albain KS. Combining nucleoside analogues and taxanes: rational and clinical data in New Horizons in Antimetabolite Therapy for Breast Cancer (oral communication). San Antonio Breast Cancer Satellite Symposium; San Antonio, TX, USA; Dec 16, 2006.
28. Cardoso F., Di Leo A., Lohrisch C., et al. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?. Ann Oncol 13 (2002) 197-207